Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
暂无分享，去创建一个
J. Moon | C. Manisty | D. Altmann | R. Boyton | M. Noursadeghi | Á. McKnight | T. Treibel | A. Semper | A. Otter | Timothy J G Brooks
[1] Leo Swadling,et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection , 2020, Science Immunology.
[2] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[3] M. Pai,et al. Will global health survive its decolonisation? , 2020, The Lancet.
[4] E. Walsh,et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.
[5] J. Moon,et al. COVID-19: PCR screening of asymptomatic health-care workers at London hospital , 2020, The Lancet.